As part of the initial public offering of the
Zur Rose Group
(ROSE), a total of 5'984'539
registered shares (before exercise of the greenshoe) were listed in accordance with the
International Reporting Standard on SIX Swiss
Exchange for the first time today (IPO video).
The opening price was CHF 151.00. This corresponds to a total market capitalization of around CHF 904 million.
The Zur Rose shares were added to the SPI®.
Stefan Feuerstein, Chairman of the Board, Zur Rose Group and Walter Oberhänsli
CEO Zur Rose Group
Capitalization of growth opportunities
With its Zur Rose and DocMorris brands, the Zur Rose Group is Europe's largest mail-order pharmacy. The company plans to use
the capital raised through the IPO to accelerate its growth strategy and to expand further its position in the European
pharmaceutical mail-order business.
"The Zur Rose Group is another internationally operating company to opt for the Swiss financial center and SIX Swiss
Exchange with it to realise its growth plans. We are very pleased about this", comments Chris Landis, Division CEO
Swiss Exchange. "We provide the platform that allows issuers to raise capital efficiently to further implement their
strategies and enable them to benefit from sustainable growth."
Numerous benefits for equity issuers
A listing on SIX Swiss Exchange provides companies with access to strongly capitalized Swiss and international investors. In
addition, we make things as simple as possible for them with first-class, needs-oriented services. Our appeal extends far
beyond the borders of Switzerland.
An overview and helpful information on all topics relevant to going public on SIX Swiss Exchange can be found
in the comprehensive Going Public Guide
or in the compact "IPO Guide Schweiz" (available only in German). Further information on our range of
services for issuers can be found on our website.
Show all news